These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 22077528

  • 1. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
    Hasselbalch HC.
    Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
    [Abstract] [Full Text] [Related]

  • 2. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.
    Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ.
    Curr Drug Targets; 2011 Mar 01; 12(3):392-419. PubMed ID: 21143149
    [Abstract] [Full Text] [Related]

  • 3. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
    Stein BL, Tiu RV.
    J Interferon Cytokine Res; 2013 Apr 01; 33(4):145-53. PubMed ID: 23570380
    [Abstract] [Full Text] [Related]

  • 4. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May 01; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 5. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
    Hasselbalch HC.
    Leuk Res; 2009 Jan 01; 33(1):11-8. PubMed ID: 18632152
    [Abstract] [Full Text] [Related]

  • 6. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
    Koopmans SM, van Marion AM, Schouten HC.
    Neth J Med; 2012 May 01; 70(4):159-67. PubMed ID: 22641623
    [Abstract] [Full Text] [Related]

  • 7. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb 01; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
    Kiladjian JJ, Chomienne C, Fenaux P.
    Leukemia; 2008 Nov 01; 22(11):1990-8. PubMed ID: 18843285
    [Abstract] [Full Text] [Related]

  • 10. Interferon in the treatment of myeloproliferative diseases.
    Silver RT.
    Semin Hematol; 1990 Jul 01; 27(3 Suppl 4):6-14. PubMed ID: 2115694
    [Abstract] [Full Text] [Related]

  • 11. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
    Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S.
    Cancer; 2007 Nov 01; 110(9):2012-8. PubMed ID: 17849460
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K, Jain T, Kosiorek H, Tibes R, Camoriano J, Palmer J, Mesa R.
    Leuk Res; 2017 Mar 01; 54():73-77. PubMed ID: 28113109
    [Abstract] [Full Text] [Related]

  • 14. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P.
    Semin Thromb Hemost; 2006 Jun 01; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J, Kantarjian H.
    Cancer; 2004 May 15; 100(10):2064-78. PubMed ID: 15139047
    [Abstract] [Full Text] [Related]

  • 17. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T.
    Acta Haematol Pol; 1992 May 15; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [Abstract] [Full Text] [Related]

  • 18. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
    Tefferi A.
    Mayo Clin Proc; 1998 Dec 15; 73(12):1177-84. PubMed ID: 9868417
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.
    Tefferi A, Vainchenker W.
    J Clin Oncol; 2011 Feb 10; 29(5):573-82. PubMed ID: 21220604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.